177Lu-FF-58

N/A

Report date: 2025/12/01 17:52:16
NME

Base Information

Drug Name177Lu-FF-58
Drug Alias Name177 lutetium labelled FF58177Lu-FF58177-Lu-FF-58177Lu-FF-58[177Lu]Lu-FF58
ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuSmall moleculesRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionIonising radiation emittersIntegrin alpha-V/beta-5 modulatorsIntegrin alpha-V/beta-3 modulators
TargetsIntegrin alpha-V/beta-5Integrin alpha-V/beta-3
Therapy Area/IndicationsStomach NeoplasmsEsophageal NeoplasmsCarcinoma, Pancreatic Ductal +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlandsSwitzerlandIsrael +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAdvanced Accelerator Applications Sa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsStomach NeoplasmsEsophageal NeoplasmsCarcinoma, Pancreatic Ductal +[4] 

Other Information

ATC CodeN/A
Related LinksN/A